Net Income

Biotech veteran Dr. Vince O'Neill joins Mosaic Therapeutics to spearhead its synergistic precision oncology pipeline, aiming to transform cancer treatment.

Parnell’s nixiFLOR, the first generic of Resflor Gold®, offers a cost-effective new weapon for ranchers battling Bovine Respiratory Disease.

XPeng reports an 80% monthly sales jump but a yearly decline, while launching a major strategic expansion into Mexico and Latin America.

Celebrating 50 years, L'Occitane en Provence balances its rich heritage with global growth, B Corp-certified sustainability, and immersive retail.

AskBio completes enrollment for a pivotal Phase 2 trial of a one-time gene therapy, potentially revolutionizing treatment for millions with heart failure.

A new report reveals why so many expats in Germany feel overwhelmed and isolated, despite most ultimately finding a better quality of life in the end.

A one-time gain gave the micro-cap a profitable quarter, but rising costs and reliance on a single large asset raise questions about its long-term stability.

A new study reveals a significant financial confidence gap between military and civilian households, highlighting the impact of unique benefits and coaching.

Investors eye Alaska Air Group's Q1 results for insights on the Hawaiian Airlines integration, rising fuel costs, and shifting travel demand.

INLIF LIMITED's 1-for-16 reverse stock split aims to secure its Nasdaq listing, but is it a strategic fix or a sign of deeper financial trouble?

A landmark case could strip healthcare giants of a key legal defense, holding them accountable for allegedly deceiving seniors into for-profit Medicare plans.

Onfolio Holdings reports 36% revenue growth and positive EBITDA, but a wider net loss and auditor warnings reveal a high-stakes strategy for 2026.

The biopharma firm touts transformative drug data ahead, but with cash for only month-to-month operations, its future hangs by a precarious thread.

A new FDA-cleared chair offers a non-invasive solution for bladder leakage, but how does the technology stack up in a rapidly growing market?

The luxury brand missed Q4 estimates, citing market challenges, but CEO Gary Friedman laid out a bold, multi-year path for global expansion and growth.

With FDA approval, soaring revenues, and game-changing clinical data, InspireMD prepares to spotlight its CGuard Prime stent for investors this April.

Banking tech leader nCino posts record FY2026 results, fueling a major stock buyback and signaling deep confidence in its AI-driven global strategy.

The carbon-tech firm slashes losses and touts a key SAF partnership, but dwindling cash reserves raise questions about its path to sustainable growth.

Facing a severe cash crunch and delisting threats, the biotech firm is halting development and seeking buyers for its innovative cancer drug pipeline.

Investors in distressed Ravelin Properties REIT are forming a group to scrutinize a $1.1B rescue deal, signaling a potential battle over its fairness.